Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7512944 | 0.86 | SMN1; SMN2 (0.48) | ALOX15PIK3CDACE2SIGMAR1CYP2D6 | |
| SCHEMBL13833162 | 0.84 | ALOX15 (0.59) | ALOX15PIK3CDACE2SIGMAR1SMN1; SMN2 | |
| SCHEMBL991986 | 0.84 | ALOX15 (0.59) | ALOX15PIK3CDACE2SIGMAR1SMN1; SMN2 | |
| SCHEMBL23471459 | 0.83 | SIGMAR1 (0.43) | ALOX15PIK3CDSIGMAR1SMN1; SMN2 | |
| SCHEMBL1070962 | 0.82 | ALOX15 (0.56) | ALOX15 | |
| SCHEMBL11371442 | 0.82 | ALOX15 (0.56) | ALOX15PIK3CDACE2SIGMAR1SMN1; SMN2 | |
| SCHEMBL20438377 | 0.82 | PIK3CD (0.61) | PIK3CDSLC2A1CYP2D6SMN1; SMN2 | |
| SCHEMBL24209746 | 0.82 | PIK3CD (0.61) | PIK3CDSLC2A1CYP2D6SMN1; SMN2 | |
| SCHEMBL2001262 | 0.82 | — | — | |
| SCHEMBL1621691 | 0.82 | PIK3CD (0.61) | PIK3CDSLC2A1CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-7407969-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-05 | — | — | US | disclosed |
| US-7407969-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-05 | — | — | US | disclosed |
| EP-0802196-B1 | Alkylenediamine derivatives as drugs for the treatment of ulcers and the inhibition of Helicobacter pylori | SHISEIDO CO LTD (JP) | 2001-08-29 | — | — | EP | disclosed |
| US-5814634-A | PEPTIC ULCERS, GASTRIC ULCERS | SHISEIDO CO. LTD. (JP) | 1998-09-29 | — | — | US | disclosed |
| EP-0802196-A1 | Alkylenediamine derivative, antiulcer drug, and antibacterial drug | SHISEIDO COMPANY LIMITED (JP) | 1997-10-22 | — | — | EP | disclosed |
| US-5326870-A | Asthma; bronchodilator agents; respiratory system disorders | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1994-07-05 | — | — | US | disclosed |
| EP-0525203-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVE OR PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | ALOX15 3177/4885PIK3CD 2136/4885ACE2 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.